Pictet Asset Management Holding SA Sells 549,622 Shares of Scholar Rock Holding Corporation $SRRK

Key Points

• Pictet Asset Management cut its Scholar Rock stake by 60.3% in the third quarter, selling 549,622 shares and retaining 361,453 shares valued at about $17.4 million.
• Director Srinivas Akkaraju bought 146,970 shares for approximately $6.1 million, increasing his holdings by 2.36% to about 6.38 million shares.
• Scholar Rock reported a quarterly loss of $0.81 per share, better than analysts’ $0.85 loss estimate; revenue of $570,000 also exceeded estimates of $300,000.

Pictet Asset Management Holding SA decreased its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 60.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 361,453 shares of the company's stock after selling 549,622 shares during the quarter. Pictet Asset Management Holding SA owned about 0.30% of Scholar Rock worth $17,416,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP purchased a new position in Scholar Rock in the 2nd quarter worth about $35,000. PNC Financial Services Group Inc. increased its holdings in shares of Scholar Rock by 92.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,270 shares of the company's stock valued at $62,000 after acquiring an additional 610 shares during the period. GAMMA Investing LLC grew its stake in Scholar Rock by 20.8% in the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company's stock valued at $77,000 after purchasing an additional 242 shares during the last quarter. IFP Advisors Inc lifted its position in Scholar Rock by 219.0% during the third quarter. IFP Advisors Inc now owns 1,560 shares of the company's stock valued at $75,000 after acquiring an additional 1,071 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Scholar Rock during the 2nd quarter valued at $99,000. 91.08% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Srinivas Akkaraju purchased 146,970 shares of the company's stock in a transaction that occurred on Monday, October 26th. The shares were purchased at an average price of $41.59 per share, for a total transaction of $6,112,482.30. Following the transaction, the director directly owned 6,380,517 shares of the company's stock, valued at approximately $265,365,702.03. The trade was a 2.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 10.30% of the stock is currently owned by corporate insiders.

Scholar Rock Price Performance

SRRK stock opened at $43.16 on Friday. Scholar Rock Holding Corporation has a 1 year low of $29.35 and a 1 year high of $61.76. The business's 50-day moving average is $46.38 and its two-hundred day moving average is $48.22. The company has a debt-to-equity ratio of 1.16, a current ratio of 5.41 and a quick ratio of 7.02. The firm has a market capitalization of $5.27 billion, a P/E ratio of -12.85 and a beta of 0.78.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.30 million. During the same period in the prior year, the company posted ($0.90) earnings per share. Analysts anticipate that Scholar Rock Holding Corporation will post -3.11 earnings per share for the current fiscal year.

Trending Headlines about Scholar Rock

Here are a few of the latest headlines about SRRK:

• Positive Sentiment: HC Wainwright raised its Q4 2026 and FY2026 EPS estimates slightly, while maintaining a Buy rating and $70 price target. Scholar Rock analyst estimates
• Negative Sentiment: Wolfe Research cut its rating on SRRK from Outperform to Peer Perform, removing a bullish endorsement and potentially contributing to near-term selling pressure. Wolfe Research ratings
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for FY2027–FY2030, including cutting FY2029 from a profit estimate to a loss and reducing projected FY2030 EPS from $1.44 to $1.00. Those reductions temper the longer-term outlook despite the firm’s Buy rating and $70 target. Scholar Rock analyst estimates

Wall Street Analyst Weigh In

SRRK has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Scholar Rock from $65.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, September 15th. Citigroup upped their price objective on shares of Scholar Rock from $60.00 to $74.00 and gave the stock a "buy" rating in a research report on Monday, September 14th. Cantor Fitzgerald reiterated a "neutral" rating and set a $70.00 target price on shares of Scholar Rock in a research report on Monday, September 21st. TD Cowen reiterated a "buy" rating on shares of Scholar Rock in a report on Monday, September 14th. Finally, Jefferies Financial Group increased their target price on shares of Scholar Rock from $57.00 to $65.00 and gave the company a "buy" rating in a research report on Monday, September 14th. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Scholar Rock has an average rating of "Moderate Buy" and an average price target of $67.67.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company's lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients' motor function.

Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.